Concepedia

Carl D. Davis

CD

Statistics

Publications

22

Citations

730

H-Index

17

Active since

1995

Affiliations

Amgen (United States)(Current)

Bristol-Myers Squibb (United States)

Bristol-Myers Squibb (Germany)

University of Liverpool

New York State Psychiatric Institute

Carl D. Davis is an author at Amgen (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1995–2021

22

Publications

22

Transient Receptor Potential Melastatin 8 (TRPM8) Channels are Involved in Body Temperature Regulation

Narender R. Gavva, Carl D. Davis, Sonya G. Lehto et al. · Molecular Pain · 2012 · 98 citations · Full text

, , +17

Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): A potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery

Prasad V. Chaturvedula, Stephen E. Mercer, Sokhom S. Pin et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 61 citations · Full text

, , +15

Discovery of TRPM8 Antagonist (<i>S</i>)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine

Daniel B. Horne, Kaustav Biswas, James Brown et al. · Journal of Medicinal Chemistry · 2018 · 61 citations · Full text

, , +15

Discovery of (<i>R</i>)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-<i>N</i>-(3-(7-methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): A Potent Antagonist of the Human Calcitonin Gene-Related Peptide Receptor for Migraine with Rapid and Efficient Intranasal Exposure

Andrew P. Degnan, Prasad V. Chaturvedula, Charles M. Conway et al. · Journal of Medicinal Chemistry · 2008 · 60 citations · Full text

, , +15

Fluorine Substitution Can Block CYP3A4 Metabolism-Dependent Inhibition:  Identification of (<i>S</i>)<i>-N</i>-[1-(4-Fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an Orally Bioavailable KCNQ2 Opener Devoid of CYP3A4 Metabolism-Dependent Inhibition

Yong‐Jin Wu, Carl D. Davis, Steven I. Dworetzky et al. · Journal of Medicinal Chemistry · 2003 · 58 citations · Full text

, , +11

1–5 of 22